| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | 0.065 | 0.6 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | -0.025 | 0.6 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.015 | 0.6 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | 0.026 | 0.6 |
| mRNA | NSC 74859 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |